Biotechnology company FairJourney Biologics has appointed Dr Werner Lanthaler as Chief Executive Officer (CEO), the company has announced.  

Lanthaler has forged an extensive career in the biopharmaceutical industry, driving innovation, transformation and sustainable growth. Lanthaler served as CEO of Evotec SE for 15 years, where he transformed the company into a global leader in drug discovery in precision medicine. Before joining Evotec, he served as CFO of Intercell, being responsible for the company’s IPO and the market launch of its vaccines. Throughout his career, Lanthaler has led collaborations to drive commercial success and long-term growth with global pharmaceutical, biotechnology, and academic institutions. 

“Shared data- and AI-driven innovation platforms will be critical to accelerating drug discovery while reducing development timelines and costs,” said Lanthaler. “FairJourney Biologics is best positioned to be the global leader in delivering significant efficiency gains resulting from the entire ‘Gene to Clone’ process for its partners. I am honoured to lead FJBio into its next growth phase.” 

FairJourney Biologics believes Lanthaler’s appointment will strengthen its global position as an integrated powerhouse of efficient antibody discovery and development. Lanthaler’s appointment also comes as FairJourney Biologics Founder, António Parada, will focus on driving the company’s innovation strategy on the Supervisory Board. 

“FairJourney Biologics is just at the beginning of its mission to lead the field of rapid antibody development,” Parada said. “Innovation will hold a central role in helping to drive transformational benefits to our partners.” 

Bruno Quinney, Content Team, DDW